Core Viewpoint - The stock of CSPC Pharmaceutical Group (01093) has increased by over 4%, currently trading at HKD 8.36 with a transaction volume of HKD 579 million, following the announcement of positive results from a Phase III clinical trial for its biosimilar drug, Secukinumab Injection [1] Group 1: Clinical Trial Results - CSPC's subsidiary, CSPC Zhongqi Pharmaceutical Co., Ltd., has developed Secukinumab Injection, which has shown clinical equivalence to the reference drug in a Phase III trial for moderate to severe plaque psoriasis [1] - The key study achieved its primary endpoint and demonstrated positive topline results, indicating that the product is clinically equivalent to the reference drug with good safety profiles [1] - No new or unexpected safety signals were reported, suggesting that the product may meet long-term safety requirements for patients [1] Group 2: Product Information - Secukinumab Injection is a fully human IgG1 monoclonal antibody and is a biosimilar to Cosentyx, which has been approved in China for indications including plaque psoriasis in patients aged 6 and above, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa [1] - The efficacy and safety of Cosentyx have been widely recognized, supporting the potential market acceptance of the biosimilar [1]
石药集团再涨超4% 司库奇尤单抗注射液III期临床试验取得顶线分析数据